Daniel Bowles, MD, explores the role of molecular testing in driving treatment decisions and its application in the initial diagnosis stage, while also discussing driver mutations, primary surgeries, and the importance of high-quality DNA and RNA, highlighting the 2-year window for durable RNA sequencing.
Marcia Brose, MD, delivers a comprehensive overview of differentiated thyroid cancer, detailing the incidence rates, histological features, genetic profiles, and phenotypic characteristics associated with this malignancy, providing valuable insights into the complex nature of the disease.
Expert oncologist Benjamin P. Levy, MD, shares his excitement for an upcoming program centered on recent data with selpercatinib versus pembrolizumab in patients with non-small cell lung cancer following ESMO 2023.
Retevmo improved progression-free survival, compared with chemotherapy with or without Keytruda in patients with RET-fusion positive non-small cell lung cancer.